Navigation Links
Scientists discover the specific types of macrophages that affect Crohn's disease severity
Date:2/28/2014

For those coping with Crohn's disease, a new research report published in the Journal of Leukocyte Biology offers hope for the development of new and more effective drugs. In the report, scientists show for the first time, precisely what type of immune cells are involved in driving the inflammation process in the disease. With this knowledge, new compounds can be identified which reduce the activity of these cells or lessen their inflammatory effects.

"By increasing the knowledge on the different macrophage subsets in the intestine and their blood counterparts, we hope to contribute to the discovery of more specific targets in Crohn's disease, increasing the efficiency of new treatments," said Olof Grip, M.D., Ph.D., a researcher involved in the work from the Department of Clinical Sciences Malm, at Lund University in Malm, Sweden.

To make this discovery, scientists studied blood and intestinal biopsy samples from healthy individuals and from people with Crohn's disease. They compared the proportions and specific characteristics of the cells between the two. The blood monocytes were classified into three different subsets, classical, intermediate and non-classical monocytes, and the intestinal macrophages into CD14hiHLA-DRdim, CD14hiHLA-Dbright and CD14loHLA-DRint. Researchers then purified these three subsets from the blood using advanced fluorescence-activated cell sorting techniques. Several functional properties of the purified cells were investigated by analyzing components that have been shown to be important in disease such as release of pro-inflammatory cytokines, matrix metalloproteinases and the ability of the monocytes to migrate toward CCL2. In people with Crohn's disease the specific subset of CD14hiHLA-DRdim macrophages is increased while the resident macrophage population is unaltered. These CD14hiHLA-DRdim macrophages are most likely derived from recruited classical blood monocytes, which are the most pro-inflammatory. This suggests that the CD14hiHLA-DRdim macrophages are driving the inflammation seen in Crohn's disease, exacerbating the inflammation and leading to tissue destruction.

"This work provides new leads for drugs and therapeutic targets for Crohn's disease and possibly other conditions that involve runaway inflammation," said John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology. "Most of our therapies for intestine inflammatory diseases like Crohn's involve non-specific immunosuppression that have variable efficacy and many side effects. These new studies suggest that targeting specific cell types could increase the ability to specifically treat disease, reduce unwanted side effects, and hopefully, help people lead healthier lives."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
2. Queens scientists seek vaccine for Pseudomonas infection
3. Scientists produce eye structures from human blood-derived stem cells
4. American Society of Plant Biologists honors early career women scientists
5. Brandeis scientists win prestigious prize for circadian rhythms research
6. Scientists discover new method of proton transfer
7. Salk scientists open new window into how cancers override cellular growth controls
8. WileyChina.com - Now Featuring Bespoke Pages for China’s Life Scientists
9. Scientists win $2 million to study new pathway in development and maintenance of lymphoma
10. UGA scientists reveal genetic mutation depicted in van Goghs sunflower paintings
11. Genetic mutation depicted in van Goghs sunflower paintings revealed by scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology: